State drug price transparency reporting is becoming an increasingly important compliance consideration for pharmaceutical manufacturers, distributors, and compounding pharmacies.
As more states adopt their own approaches to prescription drug pricing transparency, companies operating across multiple jurisdictions are facing a growing challenge: keeping up with a patchwork of requirements that can vary significantly from state to state.
The goal behind these laws is straightforward. State lawmakers want greater visibility into prescription drug pricing, price increases, acquisition costs, and other factors that can influence the cost of medications. The compliance reality, however, is considerably more complicated.
There is no single nationwide standard for state drug price transparency reporting. Instead, companies may need to monitor different reporting triggers, thresholds, deadlines, definitions, data requirements, and submission procedures depending on where they conduct business. For organizations managing a large portfolio of state licenses and regulatory obligations, drug price transparency can represent another layer of state-specific compliance that must be monitored alongside licensing and renewal requirements.
The Growth of State Drug Price Transparency Laws
Prescription drug pricing transparency has become an increasingly active area of state legislation. According to the National Conference of State Legislatures (NCSL), nearly 30 states were considering measures related to drug pricing transparency in 2025. Earlier state efforts primarily focused on reporting by manufacturers, pharmacy benefit managers (PBMs), and health plans, while newer initiatives have expanded attention to other participants in the pharmaceutical supply chain.
NCSL’s prescription drug legislation database continues to track state legislation addressing prescription drug pricing and payment, including price transparency and affordability initiatives. The database includes legislation dating back to 2015 and is updated regularly, illustrating just how active this area of state regulation has become.
For pharmaceutical companies, that activity is important because drug price transparency compliance is not a static requirement. A company that has established a process based on today’s rules may find that the process needs to change as states modify reporting thresholds, expand covered entities, introduce new reporting requirements, or change submission procedures.
One Concept, Many Different State Requirements
It may be tempting to think of drug price transparency reporting as a standardized process: identify a qualifying price increase, complete a report, and submit the information to the appropriate state agency.
In practice, the process can look very different from one state to another.
Oregon provides one example. The state’s Prescription Drug Price Transparency Program requires qualifying reporting manufacturers to register with the program and report certain new prescription drugs and price increases. For new prescription drugs introduced on or after January 1, 2025, Oregon identifies the reporting threshold aligns with the federal CMS specialty-tier threshold for a 30-day supply, which is currently $950. However, the federal CMS specialty-tier threshold is periodically adjusted and will be raised to $1,080 beginning January 2027. Annual price increase reporting can be triggered when the average price increases by at least 10% and the drug reaches the applicable price threshold. Oregon also has separate 60-day advance reporting requirements for certain planned price increases.
North Carolina takes a different approach. Under the state’s SCRIPT Act, manufacturers must report certain prescription drug price increases when the wholesale acquisition cost (WAC) is at least $100 for a 30-day supply and the price increase is 15% or greater. Annual reports are due January 31 for qualifying increases from the prior calendar year. North Carolina also requires reporting for certain new prescription drugs, with a short order initial notification requirement due within 3 days of the product’s availability for purchase in the state.
The broader point is not simply that Oregon and North Carolina have different requirements. It is that companies cannot necessarily develop one universal process and assume it will satisfy every state. The specific reporting trigger, applicable threshold, timing, required information, and definition of a covered entity can all vary.
The Challenge Is Not Simply Knowing the Rules
For a company operating in one state with a relatively limited product portfolio, monitoring drug price transparency requirements may be manageable. But for a pharmaceutical manufacturer, distributor, or compounding pharmacy operating across dozens of states, the challenge becomes considerably more complex.
The question is no longer simply whether a state has a drug price transparency law. Compliance teams must determine whether the law applies to the company, how the state defines a manufacturer or other reporting entity, whether the company’s specific products are covered, what price or percentage threshold triggers reporting, whether reporting is required for price increases or new products, whether advance notice is required, what information must be submitted, and when the submission is due, in addition to varied report data requirements that may include the disclosure of sensitive financial information.
It is also worth noting that each state handles confidential information differently. Some states are prohibited from publishing report data and must protect confidential information, while other states are required to publish report data. Sensitive financial data could be considered trade-secret and certain states have a lengthy process for requesting an exemption from public disclosure. These type of exemption requests are subject to the same short-notice deadlines, giving legal teams minimal time to prepare trade-secret claim statements.
Questions like these can become particularly challenging when the company has a large product portfolio, operates through multiple business entities, or maintains different regulatory structures across states.
Product and NDC-Level Tracking Adds Another Layer
One of the most significant operational challenges is that state drug price transparency requirements can involve product-specific data.
North Carolina, for example, requires manufacturers to provide information including the National Drug Code (NDC), drug name, acquisition information when applicable, and historical price information for certain qualifying reports.
Oregon similarly requires reporting at the NDC level for certain price transparency obligations. Its requirements can involve evaluating individual NDCs against specific price and percentage-increase thresholds.
For companies managing hundreds or thousands of products and NDCs, this creates a data-management challenge in addition to the regulatory challenge.
A pricing change that appears routine from a commercial perspective could potentially create a reporting obligation in one or more states. Without a centralized process for monitoring those changes, it can be difficult for compliance teams to determine which products have crossed a state-specific threshold and whether a reporting deadline has been triggered.
This becomes even more complicated when pricing, regulatory, legal, and compliance information exists across separate systems or departments.
Timing Can Be Just as Important as the Reporting Requirement
Another complication is that state reporting requirements are not always limited to annual filings. Some requirements are tied to specific events and can require action shortly after that event occurs.
North Carolina, for example, requires certain new prescription drug products to be reported within three days after becoming available for purchase in the state, followed by additional information within 30 days when applicable.
Oregon requires certain new prescription drug reports within 30 days of introduction and has separate 60-day advance notice requirements for certain planned price increases.
That distinction can fundamentally change how a compliance team needs to manage its responsibilities. An annual compliance calendar may be sufficient for some reporting obligations, but it is not enough when a state requires a company to identify a triggering event and act within days or weeks.
For companies with a large multi-state footprint, the ability to connect regulatory requirements with important business events becomes increasingly important.
Definitions Can Create Unexpected Compliance Questions
Another potential complication is determining whether a company or product actually falls within the scope of a particular state law.
State definitions are not necessarily interchangeable. Oregon, for example, defines a “reporting manufacturer” using specific criteria that include registration with the Oregon Board of Pharmacy, manufacturing or indirectly manufacturing FDA-approved prescription drugs available for sale in Oregon, and setting or changing the WAC of those drugs. Oregon’s rules also contain specific treatment for entities that only manufacture prescription drugs as registered 503B facilities.
That distinction is particularly relevant to organizations involved in 503A and 503B compounding, where the company’s regulatory status, products, distribution model, and state-specific requirements may not fit neatly into the framework used for traditional pharmaceutical manufacturers.
This is one reason companies should be cautious about making assumptions based solely on how they describe their business. A company may identify itself as a manufacturer, distributor, pharmacy, or compounder, but the applicable state law may use its own definition and criteria for determining who must report.
Distributors and Pharmacies Should Watch the Broader Trend
Many state drug price transparency laws specifically target manufacturers, but distributors and pharmacies should not assume these developments are irrelevant to their operations.
The pharmaceutical supply chain is interconnected, and states are increasingly examining pricing information across multiple participants. An increasing trend is that states have used different approaches to collect prescription drug pricing and cost information from manufacturers, PBMs, health plans, pharmacies, wholesalers, and other entities.
For distributors, manufacturers, and pharmacies, this means the regulatory environment surrounding pharmaceutical pricing is becoming broader and more complex.
For compounding pharmacies, particularly organizations operating across multiple jurisdictions or participating in both traditional and outsourcing models, understanding how state-specific definitions and reporting requirements apply can be especially important.
Compliance Is Becoming a Data Management Challenge
As state drug price transparency requirements become more detailed, compliance increasingly depends on the quality and accessibility of the information a company maintains.
Pricing information may reside with finance or commercial teams. Product information may be managed by regulatory or operations teams. State licensing information may sit within a separate compliance system. Legal teams may be monitoring legislative and regulatory developments independently.
The challenge is connecting all of that information.
A company may know that a product’s price changed. Its compliance team may know that a particular state has a drug price transparency requirement. But if there is no process connecting the pricing event to the applicable state requirement, an important reporting deadline can be missed.
This is where centralized regulatory tracking can provide significant value. Instead of treating state drug price transparency reporting as an isolated annual task, organizations can incorporate these requirements into a broader system for monitoring state-specific regulatory obligations.
Building a Multi-State Drug Price Transparency Strategy
For organizations operating across multiple jurisdictions, an effective drug price transparency strategy begins with understanding the requirements in every state where the company conducts business.
That means maintaining a current state-by-state view of applicable reporting requirements, including reporting thresholds, qualifying events, covered products, applicable definitions, submission deadlines, advance notice requirements, and required data.
Just as importantly, companies need a process for identifying regulatory changes. State laws and agency requirements can change through legislation, administrative rules, guidance, and updated reporting instructions. NCSL’s continuing tracking of state prescription drug legislation demonstrates the pace at which this regulatory landscape continues to develop.
Companies should also consider how pricing and product information is connected to their compliance processes. When a price change or new product launch occurs, there should be a reliable way to determine whether that event creates a reporting obligation in one or more states.
Finally, documentation matters. Companies should maintain records supporting how they determined whether a particular product, price change, or business activity triggered a state reporting obligation. This can be especially valuable when compliance decisions involve pricing calculations, historical data, product classifications, or state-specific definitions.
What This Means for Pharmaceutical Companies
State drug price transparency reporting is part of a broader trend toward increased state-level oversight of pharmaceutical pricing and the healthcare supply chain. The policy objectives may be similar from state to state, but the compliance requirements are increasingly fragmented.
For a company operating in one or two states, monitoring these requirements may be relatively straightforward. For pharmaceutical manufacturers, distributors, 503A and 503B compounding pharmacies, and other organizations operating across a large state portfolio, the challenge is significantly different.
A regulatory team may already be responsible for tracking dozens of state licensing requirements while simultaneously monitoring drug price transparency reporting, license renewals, product-specific requirements, state pharmacy laws, controlled substance regulations, compounding requirements, and other state-specific obligations.
That is a significant amount of information to manage manually.
Turning a Growing Regulatory Burden Into a Managed Process
State drug price transparency reporting is unlikely to become simpler as more states examine prescription drug pricing.
For pharmaceutical manufacturers, distributors, compounding pharmacies, and other organizations operating across multiple jurisdictions, the most effective approach is to treat state-specific reporting as part of a broader pharmaceutical regulatory compliance strategy.
The key is visibility.
Companies need to know which states apply, which products are affected, what triggers reporting, when information is due, and who is responsible for taking action. When that information is centralized and actively monitored, regulatory teams can spend less time searching for requirements and more time addressing the compliance issues that matter.
Through PharmaRegs’ State DPT Servicing, pharmaceutical companies can receive dedicated support for managing state drug price transparency requirements across their portfolios. State DPT Servicing is designed to help organizations navigate the complexities of state-level DPT reporting, including identifying applicable requirements, monitoring state-specific obligations, managing reporting deadlines, and supporting the information needed to maintain compliance. Backed by the regulatory expertise of the SLS and PharmaRegs team, State DPT Servicing gives pharmaceutical manufacturers, distributors, and compounding pharmacies a more structured way to manage an increasingly complex area of state regulatory compliance.
As state drug price transparency laws continue to evolve, having a structured process for monitoring state-specific obligations can make the difference between reacting to a deadline and being prepared for it.
This article is provided for informational purposes only and does not constitute legal advice. State drug price transparency requirements are subject to change, and companies should review current statutes, regulations, agency guidance, and reporting instructions applicable to their specific operations and products.